Apollo Endosurgery, Inc. (NASDAQ:APEN) Receives Consensus Rating of “Buy” from Brokerages

Apollo Endosurgery, Inc. (NASDAQ:APENGet Rating) has been assigned an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $12.80.

Several brokerages have issued reports on APEN. Stifel Nicolaus cut their price objective on shares of Apollo Endosurgery from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, February 23rd. Zacks Investment Research upgraded shares of Apollo Endosurgery from a “sell” rating to a “hold” rating in a report on Tuesday, May 3rd. Finally, Piper Sandler dropped their target price on shares of Apollo Endosurgery from $14.00 to $12.00 in a report on Wednesday, February 23rd.

In related news, CFO Jeffrey G. Black bought 15,000 shares of the company’s stock in a transaction on Monday, February 28th. The shares were purchased at an average cost of $5.66 per share, for a total transaction of $84,900.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 30.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of Apollo Endosurgery during the 4th quarter valued at approximately $41,000. Lazard Asset Management LLC lifted its stake in shares of Apollo Endosurgery by 57.2% during the 4th quarter. Lazard Asset Management LLC now owns 6,142 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 2,236 shares in the last quarter. Barclays PLC lifted its stake in shares of Apollo Endosurgery by 384.1% during the 3rd quarter. Barclays PLC now owns 6,772 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 5,373 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Apollo Endosurgery in the 4th quarter worth approximately $82,000. Finally, Waypoint Capital Advisors LLC purchased a new stake in Apollo Endosurgery in the 1st quarter worth approximately $58,000. Institutional investors own 94.64% of the company’s stock.

Shares of APEN opened at $4.27 on Friday. The business’s 50 day simple moving average is $5.76 and its 200-day simple moving average is $6.76. Apollo Endosurgery has a one year low of $3.79 and a one year high of $10.39. The company has a debt-to-equity ratio of 0.97, a current ratio of 7.78 and a quick ratio of 6.83. The company has a market capitalization of $171.87 million, a P/E ratio of -5.21 and a beta of 2.26.

Apollo Endosurgery (NASDAQ:APENGet Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Apollo Endosurgery had a negative net margin of 43.31% and a negative return on equity of 95.87%. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. On average, sell-side analysts anticipate that Apollo Endosurgery will post -0.83 EPS for the current fiscal year.

About Apollo Endosurgery (Get Rating)

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope.

Featured Articles

Analyst Recommendations for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.